期刊文献+

miR-103/KLF4在肺癌A549细胞及耐药细胞中的表达检测及靶向关系验证 被引量:4

Detection of expressing of miR-103/KLF4 in A549 lung cancer cells and A549/DDP resistant cells and validation of the targeted relationship
原文传递
导出
摘要 目的研究miR-103/KLF4(Krüppel样因子4)在肺癌A549细胞及耐药细胞中的表达及其靶向关系。方法培养肺癌细胞系A549及耐药细胞系A549/DDP(顺铂)。采用噻唑蓝(MTT)检测细胞的存活率,RT-PCR和Western blot等方法测定两细胞株中miR-103/KLF4的表达情况,双荧光素酶报告基因实验对二者的靶向关系进行验证。结果 miR-103在耐药株细胞A549/DDP中存在高表达,KLF4在耐药株细胞A549/DDP中表达明显降低。在肺癌细胞中,miR-103可以直接靶向KLF4-3'非翻译区(3'UTR)。结论在A549/DDP中miR-103可以直接靶向调控KLF4。 Objective To study the expression and targeted relationship of miR-103/KLF4 ( Kruppel like factor) in A549 and resistant cell lines of lung cancer. Methods To culture the A549 cell lines and A549/DDP (cisplatin) resistant cell lines in vitro and detect survival rates by methyl thiazolyl tetrazolium (MTF) method. Real-time polymerase chain reaction (RT-PCR) and Western blotting were used to test the expression of miR-103/KLF4 of these cell lines. Dual-luciferase reporter gene experiment to detect the targeted relationship. Results A higher expression of miR-103 and a obvious lower expression of KLF4 were observed in A549/DDP resistant cell lines. MiR-103 target KLF4-3′ UTR (3′untranslated regions) directly in lung cancer cells. Conclusions In A549/DDP resistant cells, miR-103 can regulate KLF4 at target.
作者 刘胜岗 杨红忠 Liu Shenggang, Yang Hongzhong(The Diagnostic and Therapeutic Centre of Respiratory Diseases, Changsha Central Hospital, Changsha 410000, China)
出处 《中国医师杂志》 CAS 2018年第3期402-407,共6页 Journal of Chinese Physician
关键词 微RNAs/代谢 Kruppel样转录因子类 肺肿瘤/病理学/代谢 抗药性 肿瘤 MicroRNAs/ME Krnppel-like transcription factors/ME Lung neoplasms/PA/ME Drug resistance, neoplasm
  • 相关文献

参考文献1

二级参考文献15

  • 1Chen C Z, Li L, Lodish H F, et al. MiRNA modulate hemato poietic lineage differentiation[J]. Science,2004, 303(5654): 83- 86.
  • 2Bartel D P. MiRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281- 297.
  • 3Blower P E, Chung J H, Verduai J S, et al. MiRNAs modulate the chemosensitivity of tumor cells[J]. Mol Cancer Ther, 2008, 7(1) :1-9.
  • 4Pascal S,Charles D. Chemoresistance in non small cell lung cancer[J]. Curr MedChem, 2005, 5(1):73-88.
  • 5Stewart D J. Mechanisms of resistance to cisplatin and carboplatin[J]. Crit RevOncol Hematol, 2007,63(1):12- 31.
  • 6H Zhu, H Wu, X P Liu, et al. Role of MiRNA miR 27a and miR-451 in the regulation of MDR1/P glycoprotein expression in human cancer cells[J]. Biochemical Pharmacology, 2008, 76 (5) : 582-588.
  • 7Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372-379.
  • 8Kovalchuk O, Filkowski J, Meservv J, et al. Involvement of miR NA-451 in resistance of the MCF7 breast cancer ceils to chemothera peutic drug doxorubicin[J]. Mol Cancer Ther, 2008, 7 (7):2152- 2159.
  • 9Meng F, Henson R, Lang M, et al. Involvement of human mi RNA in growth and response to chemotherapy in human cholan giocarcinoma cell lines[J]. Gastroenterology, 2006, 130 (7):2113-2129.
  • 10Chan J A, Krichevsky A M, Kosik K S. MiRNA-21 is an anti apoptotic factor in human glioblastoma cells[J]. Cancer Res, 2005, 65(14):6029- 6033.

共引文献22

同被引文献29

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部